Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06596694 · ClinicalTrials.gov registry record · Phase 1
Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)
A Phase 1 study of Gastrointestinal Cancer, sponsored by Merck Sharp & Dohme.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 180
- Enrollment target
- 20
- Study locations
NCT06596694: Recruiting Phase 1 study of Gastrointestinal Cancer, sponsored by Merck Sharp & Dohme.
NCT06596694 is a Phase 1 study of Gastrointestinal Cancer that is actively recruiting participants, run by Merck Sharp & Dohme. The registered enrollment target is 180 participants, below the 226-participant average among 49 other Gastrointestinal Cancer trials with a reported enrollment target (20% lower). The trial reports 20 study locations across 17 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06596694, a Phase 1 study of Gastrointestinal Cancer, is actively recruiting participants, sponsored by Merck Sharp & Dohme.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 180 participants
- Enrollment target
- 20
- Study locations
Study Summary
Researchers want to learn if patritumab deruxtecan (MK-1022) can treat certain gastrointestinal (GI) cancers. The GI cancers being studied are advanced (the cancer has spread to other parts of the body). The goals of this study are to learn: * About the safety and how well people tolerate of patritumab deruxtecan * How many people have the cancer respond (get smaller or go away) to treatment
Primary Outcome
DLT will be defined as any drug-related adverse event observed during the DLT evaluation period that results in a change to a given dose or a delay in initiating the next 21-day cycle. The number of participants in the dose-escalation phase who experience a DLT will be presented.
Conditions Studied
Interventions
- BIOLOGICAL Patritumab deruxtecan
Study Locations (20)
Florida
- University of Florida ( Site 1202) - Gainesville
- Mount Sinai Medical Center Comprehensive Cancer Center ( Site 1213) - Miami Beach
New York
- NYU Langone Hospital - Long Island ( Site 1230) - Mineola
- Perlmutter NYU Cancer Center ( Site 1212) - New York
Victoria
- Alfred Health ( Site 0102) - Melbourne
- Austin Health ( Site 0103) - Melbourne
California
- UCLA Hematology Oncology Santa Monica ( Site 1205) - Santa Monica
Colorado
- University of Colorado Cancer Center ( Site 1200) - Aurora
District of Columbia
- Sibley Memorial Hospital ( Site 1208) - Washington D.C.
Georgia
- Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research ( Site 1203) - Marietta
Illinois
- University of Chicago Medical Center ( Site 1204) - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2024-11-03 |
| Est. Completion | 2028-12-07 |
| Phase | Phase 1 |
What NCT06596694 shows while recruiting
NCT06596694 is an interventional study that assigns participants to a tested intervention. The registered 180 participants enrollment target is mid-sized for trials with a published cap, below the 226-participant average among 49 other Gastrointestinal Cancer trials with a reported enrollment target (20% lower).
The record links to 1 condition, with Gastrointestinal Cancer appearing as the primary indexed condition, and to 1 intervention - of which Patritumab deruxtecan is the first listed.
NCT06596694 names 20 study sites across 17 states, led by Florida, New York, Victoria.
Frequently Asked Questions
What is clinical trial NCT06596694 about?
NCT06596694 is a clinical study titled "Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)". Researchers want to learn if patritumab deruxtecan (MK-1022) can treat certain gastrointestinal (GI) cancers. The GI cancers being studied are advanced (the cancer has spread to other parts of the body). The goals of this study are to learn: * About the safety and how well people tolerate of patrit...
What is the current status of trial NCT06596694?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 180 participants. The study started on 2024-11-03. Estimated completion is 2028-12-07.
What conditions does trial NCT06596694 study?
This clinical trial studies the following conditions: Gastrointestinal Cancer.
What interventions are being tested in trial NCT06596694?
The interventions under investigation include: Patritumab deruxtecan (BIOLOGICAL).
Who is sponsoring clinical trial NCT06596694?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06596694 being conducted?
This trial has 20 study locations across California, Colorado, District of Columbia, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastrointestinal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06596694's enrollment target sits among peer trials
180 17th of 49 higher than 32 of 49 other Gastrointestinal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Gastrointestinal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RECRUITING · Phase 1
-
Individualized Response Assessment to Heated Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Peritoneal Carcinomatosis From Ovarian, Colorectal, Appendiceal, or Peritoneal Mesothelioma Histologies
RECRUITING · Phase 1
-
Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients
RECRUITING · Phase 1
-
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
RECRUITING · Phase 1
-
Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer
RECRUITING · Phase 1
-
Remote Resistance Exercise Powering Survivors - Gastrointestinal Oncology
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01558804 · 180 participants
GRoup A StrePtococcus
- NCT02932176 · 180 participants
Machine Learning for Handheld Vascular Studies
- NCT03384563 · 180 participants · Phase 4
Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane
- NCT03423628 · 180 participants · Phase 1
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI